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High-Frequency Binge Eating Predicts Weight Gain Among
Veterans Receiving Behavioral Weight Loss Treatments
Robin M. Masheb1,2, Lesley D. Lutes3, Hyungjin Myra Kim4,5, Robert G. Holleman4, David E. Goodrich4, Carol A. Janney4,
Susan Kirsh6,7, Caroline R. Richardson4, and Laura J. Damschroder4
Objective: To assess for the frequency of binge eating behavior and its association with weight loss in
an overweight/obese sample of veterans.
Methods: This study is a secondary analysis of data from the ASPIRE study, a randomized effectiveness
trial of weight loss among veterans. Of the 481 enrolled veterans with overweight/obesity, binge eating
frequency was obtained by survey for 392 (82%).
Results: The majority (77.6%) reported binge eating, and 6.1% reported high-frequency binge eating.
Those reporting any binge eating lost 1.4% of body weight, decreased waist circumference by 2.0 cm,
and had significantly worse outcomes than those reporting never binge eating who lost about double the
weight (2.7%) and reduced waist circumference by twice as much (4.2 cm). The high-frequency binge
group gained 1.4% of body weight and increased waist circumference by 0.3 cm.
Conclusions: High rates of binge eating were observed in an overweight/obese sample of veterans
enrolled in weight loss treatment. The presence of binge eating predicted poorer weight loss outcomes.
Furthermore, high-frequency binge eating was associated with weight gain. These findings have opera-
tional and policy implications for developing effective strategies to address binge eating in the context of
behavioral weight loss programs for veterans.
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Introduction
Obesity is one of the most serious public health problems faced by
our nation. While two-thirds of Americans are overweight/obese (1),
the prevalence of overweight and obesity is greater among certain
high-risk patient populations including the patients served by the
veterans health administration (VHA); nearly 77% of veterans are
classified as overweight/obese (2). While binge eating disorder
(BED) is closely associated with obesity and is the most common
eating disorder in the United States, it is understudied among veter-
ans (3-5).
In 2013, BED was included in the revision of the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (6)
as a clinical disorder. Specifically, BED is defined as eating unusu-
ally large amounts of food, while experiencing a subjective sense of
loss of control, on average at least once a week for 3 months or
more. BED is strongly associated with high rates of psychiatric and
medical comorbidity, confers a greater risk for obesity-related ill-
nesses beyond that conferred by obesity alone (7), and affects
30% of individuals from the general population who seek weight
loss treatment and who are predominately female (8).
Individuals who binge eat may be an especially vulnerable subgroup
of the overweight population, regardless of whether or not they meet
DSM-5 diagnostic criteria for BED. This is best exemplified by a
national study of over 45,000 veterans in which individuals report-
ing binge behavior were significantly more likely to report a broad
range of comorbid mental health and medical conditions than those
who reported no binge eating (9). While little is known about the
prevalence of BED among veterans using DSM-5 diagnostic criteria,
as many as 78% of veterans affected by overweight/obesity and eli-
gible for the VHA’s national weight management program,
MOVE!VR , report binge eating (9).
A number of psychological treatments for BED have demonstrated
robust effects for reducing and/or eliminating binge eating, and
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improving the behavioral and psychological aspects of the disorder.
Despite these significant improvements in binge eating and associ-
ated behaviors, there is a minimal effect on weight loss (10). Clini-
cal trials have reported only modest associations between binge
remission and weight loss (10-12), and it has yet to be determined
why substantial reductions in binge eating behavior are generally
associated with only minimal reductions in weight (13).
Little has been done to examine binge eating as a predictor of
weight loss treatment (14-17). A negative association has been
found between the presence of BED and weight loss in Latino/as
(15), and among individuals with overweight/obesity and type 2 dia-
betes participating in the Look AHEAD study (Action for Health in
Diabetes) (16). However, in a third study of patients with over-
weight/obesity in primary care, the presence of BED status was not
associated with weight loss outcomes, but was associated with
behavioral treatment adherence (17).
Given that overweight/obesity are the most prevalent medical condi-
tions among veterans and new evidence suggesting potentially high
rates of binge eating in this high-risk group (9,18), we sought to
investigate rates of binge eating among veterans who were seeking
weight loss treatment, and to determine whether weight outcome dif-
fered by binge eating status.
Methods
Study design
This is a secondary data analysis comparing weight loss and clinical
outcomes based on binge eating status among veterans who are over-
weight/obese. Participant data were obtained from the ASPIRE-VA
trial (19,20), a randomized clinical effectiveness trial of 481 veterans
recruited for routine weight management. The trial was designed to
evaluate the effectiveness of a small changes weight loss intervention,
ASPIRE, compared to the VHA national weight management
program, MOVE! ASPIRE encourages participants to make small,
self-selected goals resulting in an energy deficit as small as 200 kcal/
day that may be sufficient to promote weight loss and maintenance
over time (19). MOVE!, the “usual care” weight management avail-
able to veterans served by VHA, was based upon evidence-based
guidelines from the National Institutes of Health and the 2003 US
Preventive Services Task Force. MOVE! utilizes an open-group for-
mat (i.e., patients can join the group at any time), on-line materials,
and multidisciplinary team of health psychologists, dietitians, and
physical therapists. For both ASPIRE and MOVE!, 3 months of
weekly treatment was followed by 9 months of maintenance (sessions
occurring biweekly for six months and then monthly).
Participants from two VHA sites were randomized to one of three
treatment arms and stratified by site: (1) the ASPIRE weight loss
program delivered individually over the phone (ASPIRE-Phone); (2)
the ASPIRE weight loss program delivered via in-person group ses-
sions (ASPIRE-Group); or (3) MOVE! the VHA’s national weight
management program, delivered as usual care. Institutional review
board approval was obtained at both sites.
Participants and procedures
Eligible veterans were primary care provider- or self-referred for
weight management services and eligible for MOVE! treatment at
two Midwestern VA medical centers. Candidates were invited to par-
ticipate if they had a BMI 30 kg/m2, or between 25 and 30 kg/m2
and at least one obesity-related health condition (e.g., type 2 diabe-
tes). Other inclusion criteria included an ability to communicate in
English and ability to provide informed consent, as well as reliable
access to a telephone. Exclusionary criteria were as follows: current
enrollment in another weight loss, nutrition, or physical activity study;
current involvement in another weight loss treatment or medication;
inability to complete a 6-min walking test; or pregnancy. An addi-
tional study criterion included completion of a binge eating frequency
item (described below) to determine binge status. Of the 481 partici-
pants randomized to ASPIRE, the effective sample size for this study
was N5 392 as binge eating status information was missing for 89
original cohort participants. There were no significant differences in
demography, or clinical characteristics, between those with and with-
out the binge eating status information. Enrollment began January
2010 and all 12-month follow-up assessments were completed by
November 2012.
Binge status and measures
Prior to randomization, participants completed the MOVE!23 Sur-
vey, a clinical instrument developed to aid in tailoring weight man-
agement treatment for veterans by administering the survey prior to
engaging in MOVE! and evaluating each individual’s unique treat-
ment needs (21). The 23-item questionnaire assesses a number of
domains related to weight management; however, because it is not a
research instrument, limited psychometric validation has been con-
ducted (22). Only the binge eating behavior item from the
MOVE!23 Survey was used for this study. This is a self-report item
that asks, “On average, how often have you eaten extremely large
amounts of food at one time and felt that your eating was out of
control at that time?” The response set for this item is never, less
than one time per week, one time per week, two to four times per
week, or five or more times per week. At baseline, demographic and
clinical data were obtained for descriptive purposes. Psychiatric
(post-traumatic stress disorder (PTSD) and substance use) disorders
and medical diagnoses were obtained from medical records to com-
pute the Charlson Comorbidity Index (CCI). The CCI is a validated
measure indicating burden of disease based upon age and presence
of 19 conditions with high likelihood of mortality (23). The Satis-
faction with Life Scale (24) was also administered as part of the
baseline assessment survey.
We chose two a priori methods for categorizing participant binge
eating status. In the first method, we categorized participants using a
previously reported strategy that distinguished veterans with high
rates of psychiatric and medical comorbidities using the MOVE!23
binge frequency item (9). Those who responded “never” to the
MOVE!23 binge frequency item were categorized as NO BINGE,
and those who reported “less than one time per week” or more were
categorized as ANY BINGE. The second method was based upon
previously published studies where the mean frequency of binge eat-
ing behavior was approximately 4.5 episodes per week among
patients meeting DSM-5 criteria for BED and seeking weight loss
treatment (23,24). Thus, in the second method, participants who
reported “five or more times per week” were categorized as HIGH
BINGE and all others were categorized as NOT HIGH.
The primary outcome for this study was percent weight loss, both
continuously and categorically (i.e., attainment of 5% weight loss).
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For descriptive purposes, results were also presented for weight (kg),
BMI [weight (kg)/height (m2)], and waist circumference (cm).
Exploratory analyses were performed for secondary outcomes includ-
ing dietary outcomes as measured by the self-reported Food Fre-
quency Questionnaire (25), and metabolic outcomes as measured by
lipid profile analysis and blood pressure. Measures were assessed at
three time points; participants received remuneration for completing
assessments at baseline ($20), 3 months ($20), and 12 months ($50).
Statistical analyses
Descriptive statistics were calculated for all variables using Pearson
Chi-square test for categorical variables and analysis of variance for
continuous variables. One-sided linear mixed models were used to
model the longitudinal change in outcomes at 3 and 12 months post-
randomization. Two separate models were built for each of the a
priori set of binge eating categories with either NO BINGE or NOT
HIGH as the reference group. The following independent variables
were controlled for in the models: treatment arm, baseline value of
the outcome variable, binge eating status, time, and time by binge
eating status interaction. It is important to note that given that the
main focus of this study was to examine treatment outcome by
binge status, participants were pooled together across treatment arms
and treatment arm was controlled for in analyses. Finally, chi-square
analyses were conducted to examine whether those in the lower
binge status groups were more likely to achieve 5% or greater
weight loss compared to the high binge status groups, and more
likely to complete treatment. All analyses were performed in Stata,
version 13.1 (College Station, TX).
Results
Demographic clinical and treatment
characteristics, and binge frequency
The sample was predominately middle aged (M5 55.4, SD5 10.0),
moderately obese (M BMI5 36.4, SD5 6.1) men (n5 333, 84.9%)
composed of 57.7% (n5 226) White, 40.3% (n5 158) African
American, and 2% (n5 8) “other” race. With regard to weight sta-
tus, 10.7% (n5 42) were overweight and 89.2% (n5 350) were
obese. In terms of randomization, 128 (32.7%) were assigned to
ASPIRE-Phone, 132 (33.7%) to ASPIRE-Group, and 132 (33.7%) to
MOVE! Participants completed an average of 12.8 (SD5 9.3) ses-
sions and there was a significant difference in sessions completed
by treatment arm. Specifically, participants in both the ASPIRE-
Phone (M5 15.2) and ASPIRE-Group (M5 12.9) attended signifi-
cantly more sessions compared with MOVE! (M5 5.5). For the
overall sample, rates of PTSD and substance use disorders were
16.8 and 17.1%, respectively, the mean CCI was 1.2 comorbid con-
ditions (SD5 1.5, range 0-9), and mean life satisfaction was 3.8
(SD5 1.5, range 1-7).
Overall, 77.6% (n5 304) of participants reported any binge eating,
with almost half (47.7%; n5 187) reporting binge eating one or
more times per week and 6.1% (n5 24) reporting five or more times
per week (see Table 1).
The NO BINGE group had a significantly lower mean baseline
weight and BMI compared to the ANY BINGE group (P’s< 0.05)
and had a significantly smaller proportion of participants with PTSD
(8 vs. 19.4%, P5 0.01), whereas the NOT HIGH and HIGH BINGE
groups did not differ on baseline weight or BMI, or presence of
PTSD. The NOT HIGH group reported significantly greater life sat-
isfaction than the HIGH BINGE group (P5 0.03). No significant
differences were found between sex, age, race, presence of sub-
stance use disorders, or CCI on either binge status comparison (i.e.,
NO BINGE vs. ANY BINGE, or NOT HIGH vs. HIGH BINGE).
See Tables 2 and 3 for comparisons of baseline demographic and
clinical characteristics.
Comparisons by binge status
There were significant differences on the primary percent weight
loss outcome by binge status. The NO BINGE group had signifi-
cantly greater mean percent weight loss and significantly greater
mean reduction in waist circumference than the ANY BINGE group.
At 12 months the NO BINGE group lost 2.7% of body weight and
waist circumference decreased by 4.2 cm, whereas the ANY BINGE
group lost 1.4% of body weight and waist circumference decreased
by 2.0 cm (P5 0.029 and P5 0.008, respectively). Differences in
weight change (kg) and BMI approached significance (P5 0.054
and P 50.056, respectively). These findings held even when con-
trolling for PTSD status. Figure 1 depicts the weight changes (kg)
from baseline to 12 months post-treatment for the NO BINGE and
ANY BINGE groups. No significant differences between the NO
BINGE and ANY BINGE groups were observed for the secondary
dietary and metabolic outcomes. See Table 4 for comparison of the
NO BINGE and ANY BINGE groups.
There were significant differences on the primary percent weight loss
outcome and all other weight outcomes using the second categoriza-
tion method as well. The NOT HIGH group had significantly greater
mean percent weight loss, and greater reductions in weight (kg),
BMI, and waist circumference than the HIGH BINGE group. At 12
months the HIGH BINGE group gained 1.4% of body weight and
waist circumference increased by 0.3 cm, whereas the NOT HIGH
group lost 1.9% of body weight and waist circumference decreased
by 2.7 cm (P5 0.001 and P5 0.029, respectively). Figure 2 depicts
the weight changes (kg) from baseline to 12 months post-treatment
for the NOT HIGH and HIGH BINGE groups. There were no signifi-
cant differences between the NOT HIGH and HIGH BINGE groups
on secondary measures for dietary and metabolic outcomes. See Table
5 for comparisons of the NOT HIGH and HIGH BINGE groups.
Five percent weight loss
Overall, 21.6% (n5 75) of the 348 participants with post-treatment
weight data achieved clinically significant weight loss (i.e., at least 5%
weight loss). Participants in the NO BINGE group were not
TABLE 1 Frequency of binge eating from the MOVE!23 Survey
(N5392)
Frequency n %
Never (NO BINGE) 88 22.4
Less than 1 time per week 117 29.9
1 time per week 62 15.9
2–4 times per week 101 25.8
5 or more times per week (HIGH BINGE) 24 6.1
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significantly more likely to achieve 5% weight loss compared with the
ANY BINGE group [25.6% (20/78) vs. 20.4% (55/270); v2 (1)5 0.99,
P5 0.319]. However, participants in the NOT HIGH group were signif-
icantly more likely to achieve 5% weight loss compared with the HIGH
BINGE group [22.8% (74/325) vs. 4.4% (1/23); v2(1)5 4.31,
P5 0.038].
TABLE 2 Demographic and clinical characteristics of the total sample by NO BINGE and ANY BINGE status (N5392)
NO BINGE ANY BINGE Total P-value
n 88 304 392
Sex (male), n (%) 76 (86.4) 257 (84.5) 333 (84.9) 0.673
Age category (years), n (%) 0.676
<50 24 (27.3) 75 (24.7) 99 (25.3)
50-59 31 (35.2) 99 (32.6) 130 (33.2)
601 33 (37.5) 130 (42.8) 163 (41.6)
Race, n (%) 0.344
African-American 41 (46.6) 117 (38.5) 158 (40.3)
Other 1 (1.1) 7 (2.3) 8 (2.0)
White 46 (52.3) 180 (59.2) 226 (57.7)
Baseline weight (kg), mean (SD) 107.2 (18.2) 114.1 (23.6) 112.6 (22.7) 0.012
Baseline BMI, mean (SD) 34.8 (4.7) 36.9 (6.4) 36.4 (6.1) 0.004
Baseline BMI category 0.016
>25-29.9 15 (17.0) 27 (8.9) 42 (10.7)
30-39.9 59 (67.0) 192 (63.2) 251 (64.0)
40 14 (15.9) 85 (28.0) 99 (25.3)
PTSD, n (%) 7 (8.0) 59 (19.4) 66 (16.8) 0.011
Substance use disorder, n (%) 16 (18.2) 51 (16.8) 67 (17.1) 0.767
Charlson Comorbidity Index, mean (SD) 1.0 (1.3) 1.2 (1.6) 1.2 (1.5) 0.263
Life Satisfaction, mean (SD) 3.9 (1.5) 3.8 (1.5) 3.8 (1.5) 0.521
TABLE 3 Demographic and clinical characteristics of the total sample by NOT HIGH and HIGH BINGE status (N5392)
NOT HIGH HIGH BINGE Total P-value
n 368 24 392
Sex (male), n (%) 315 (85.6) 18 (75.0) 333 (84.9) 0.159
Age category (years), n (%) 0.614
<50 93 (25.3) 6 (25.0) 99 (25.3)
50–59 120 (32.6) 10 (41.7) 130 (33.2)
601 155 (42.1) 8 (33.3) 163 (41.6)
Race, n (%) 0.713
African-American 149 (40.5) 9 (37.5) 158 (40.3)
Other 8 (2.2) 0 (0.0) 8 (2.0)
White 211 (57.3) 15 (62.5) 226 (57.7)
Baseline weight (kg), mean (SD) 112.4 (22.6) 114.9 (23.5) 112.6 (22.7) 0.610
Baseline BMI, mean (SD) 36.3 (6.0) 38.7 (7.7) 36.4 (6.1) 0.056
Baseline BMI category 0.360
>25–29.9 40 (10.9) 2 (8.3) 42 (10.7)
30–39.9 238 (64.7) 13 (54.2) 251 (64.0)
40 90 (24.5) 9 (37.5) 99 (25.3)
PTSD, n (%) 62 (16.8) 4 (16.7) 66 (16.8) 0.982
Substance use disorder, n (%) 61 (16.6) 6 (25.0) 67 (17.1) 0.291
Charlson Comorbidity Index, mean (SD) 1.2 (1.5) 0.8 (1.3) 1.2 (1.5) 0.275
Life Satisfaction, mean (SD) 3.8 (1.5) 3.2 (1.3) 3.8 (1.5) 0.027
NOT HIGH5 less than five binge episodes per week; HIGH BINGE5greater or equal to five binge episodes per week.
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Treatment completion
Overall, 88.8% (n5 348) of the 392 randomized participants com-
pleted the 12-month post-treatment weight assessment, including the
measurement of weight. Participants in the NO BINGE group were
not significantly more likely to complete treatment compared with
the ANY BINGE group [88.6% (78/88) vs. 88.8% (270/304); v2
(1)5 0.00, P5 0.963]. Participants in the NOT HIGH group were
also not significantly more likely to complete treatment compared
with the HIGH BINGE group [88.3% (325/368) vs. 95.8% (23/24);
v2(1)5 1.28, P5 0.258]. There were no significant differences
between binge eating status groups for the number of treatment ses-
sions attended (NO BINGE5 12.2, SD5 9.1 vs. ANY
Figure 1 Predicted weight change at 3 and 12 months for veterans classified as
NO BINGE or ANY BINGE based on linear mixed effects models controlling for
treatment arm, baseline weight, binge eating status [NO BINGE vs. ANY BINGE],
visit, and visit by binge eating status interaction.
TABLE 4 Adjusted comparison of various outcomes for NO BINGE (n588) and ANY BINGE (n5 304) groups
Baselinea 12-month changeb
Outcome NO BINGE ANY BINGE P-value NO BINGE ANY BINGE P-value
Primary outcome
% Weight loss 0.0 0.0 22.7 (23.8, 20.8) 21.4 (22.0, 20.8) 0.029
Secondary weight outcomes
Weight (kg) 108 (104, 112) 115 (112, 117) 0.002 22.9 (24.0, 20.9) 21.6 (22.2, 20.9) 0.054
BMI (kg/m2) 34.9 (33.9, 35.9) 37.0 (36.3, 37.7) 0.001 20.9 (21.3, 20.3) 20.5 (20.7, 20.3) 0.056
Waist (cm) 118 (115, 120) 121 (119, 122) 0.054 24.2 (25.6, 21.3) 22.0 (22.8, 21.3) 0.008
Secondary dietary outcomes
Fruit/veg (servings) 4.6 (4.2, 5.1) 4.5 (4.3, 4.7) 0.686 0.1 (20.3, 0.6) 0.3 (0.1, 0.6) 0.307
% Fat (g) 35.1 (34.1, 36.1) 35.0 (34.4, 35.6) 0.876 20.8 (22.0, 20.5) 21.1 (21.7, 20.5) 0.691
Fiber (g) 20.3 (18.1, 22.6) 20.4 (19.3, 21.4) 0.975 2.7 (20.4, 1.7) 0.2 (21.3, 1.7) 0.150
Secondary metabolic outcomes
LDL (mg/dl) 109 (101, 117) 108 (105, 112) 0.917 23.4 (29.3, 1.1) 22.0 (25.1, 1.1) 0.698
HDL (mg/dl) 38 (36, 40) 38 (37, 39) 0.903 2.3 (0.6, 3.3) 2.5 (1.6, 3.3) 0.856
Triglycerides (mg/dl) 157 (137, 177) 167 (154, 179) 0.386 211.4 (232.7, 8.5) 22.5 (213.6, 8.5) 0.471
Hemoglobin (A1c) HbA1c 6.4 (6.2, 6.6) 6.5 (6.3, 6.6) 0.423 20.0 (20.2, 0.0) 20.1 (20.2, 0.0) 0.538
Systolic (mm Hg) 125 (122, 128) 128 (126, 130) 0.069 20.8 (24.0, 3.1) 1.4 (20.3, 3.1) 0.223
Diastolic (mm Hg) 77 (75, 80) 79 (78, 80) 0.268 0.3 (21.7, 1.2) 0.1 (20.9, 1.2) 0.884
aUnadjusted means at baseline.
bPredicted 12-month changes for each outcome variable based on linear mixed models. Independent variables included time (3 or 12 months), treatment arm, baseline
value of the outcome variable, binge eating status [NO BINGE (reference) vs. ANY BINGE], time, and time by binge eating status interaction.
Figure 2 Predicted weight change at 3 and 12 months for veterans classified as
NOT HIGH or HIGH BINGE based on linear mixed effects models controlling for
treatment arm, baseline weight, binge eating status [NOT HIGH vs. HIGH BINGE],
visit, and visit by binge eating status interaction.
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BINGE5 12.9, SD5 9.4, t520.63, P5 0.53; NOT HIGH5 13.0,
SD5 9.3 vs. HIGH BINGE5 10.0, SD5 9.3, t5 1.53, P5 0.13).
Discussion
This is the first study to investigate the potential negative implica-
tions of binge eating among veterans seeking weight loss treatment
through the VHA. Overall, high rates of self-reported binge eating
episodes were observed in this sample of veterans with overweight/
obesity who enrolled in a clinical trial of weight loss. Over three-
quarters (78%) reported any binge eating, 72% reported less than
one time per week to four times per week, and 6% reported high-
frequency binge eating (five or more times per week) similar to
patients with DSM-5 diagnosed BED who enrolled in clinical trials
for weight loss and binge eating treatments (26,27).
Additionally, binge eating, particularly high-frequency binge eating,
predicted worse weight outcomes. Those without binge eating lost
almost twice as much weight and reduced their waist size by more
than double compared to those with any binge eating after 12
months. The much higher rate of PTSD in the any binge group did
not account for the differences in weight. Even more striking were
findings for those reporting high-frequency binge eating. Those indi-
viduals on average gained weight and waist circumference
increased. Nearly one-quarter of the no/low-frequency binge group
participants achieved clinically significant weight loss (i.e., at least
5% of body weight), whereas only 4% of the high-frequency binge
group did so. Despite the disparate weight outcomes, veterans com-
pleted treatment at similar rates, and attended a similar number of
sessions, regardless of binge status.
These findings have important implications because evidence for the
negative implications of binge eating on weight loss, even amongst
individuals with BED, is poorly understood (28). Consistent with
studies examining the prognostic significance of BED in predomi-
nately female samples (14-16), we found that binge eating was a
negative prognostic indicator for weight loss. Contrary to studies
that found greater attrition (29) and lower treatment adherence (17),
however, we did not find that binge eating predicted higher attrition
or lower session attendance among veterans in this study.
The most notable limitation of this study was the assessment of
binge eating frequency with a single self-report item. It is not known
whether this item is reliable, or how valid the categorical response
set is compared to state-of-the-art measures, such as the clinician
administered Eating Disorder Examination (30) or the self-report
version, the Eating Disorder Examination-Questionnaire (EDE-Q)
(31), which utilize continuous data for measuring binge episodes.
While a severity specifier for BED was added to DSM-5 (6) (e.g.,
mild is 1–3 binge eating episodes per week), we know of no study
that has validated these categories. Thus, it is noteworthy that the
binge assessment used here identified two potentially important sub-
groups of veterans with overweight/obesity. One subgroup, the any
binge eaters, was less successful at weight loss, and a second sub-
group, the high-frequency binge eaters, actually gained weight dur-
ing the course of weight management treatment.
Participants in this study were mostly older male veterans who were
overweight/obese and who participated in a weight loss clinical trial
through the VHA in two Midwestern states. Findings may not
generalize to non-veterans, or veterans who: are overweight/obese
TABLE 5 Adjusted comparison of various outcomes for NOT HIGH (n5 368) and HIGH BINGE (n524) groups
Outcome
Baselinea 12-month changeb
NOT HIGH HIGH BINGE P-value NOT HIGH HIGH BINGE P-value
Primary outcome
% Weight loss 0.0 0.0 21.9 (22.4, 21.4) 1.4 (20.5, 3.3) 0.001
Secondary weight outcomes
Weight (kg) 113 (111, 115) 113 (104, 122) 0.957 22.1 (22.7, 21.5) 1.6 (20.6, 3.7) 0.001
BMI (kg/m2) 36.4 (35.8, 37.0) 37.9 (34.8, 40.9) 0.328 20.7 (20.9, 20.5) 0.5 (20.2, 1.2) 0.001
Waist (cm) 112 (118, 121) 121 (114, 129) 0.666 22.7 (23.4, 22.0) 0.3 (22.3, 3.0) 0.029
Secondary dietary outcomes
Fruit/veg (servings) 4.6 (4.4, 4.8) 4.5 (3.7, 5.2) 0.785 0.3 (0.1, 0.5) 0.2 (20.6, 1.0) 0.833
% Fat (g) 34.9 (34.4, 35.4) 36.6 (33.8, 39.4) 0.233 21.0 (21.6, 20.4) 21.8 (23.8, 0.2) 0.449
Fiber (g) 20.4 (19.4, 21.4) 20.0 (16.2, 23.7) 0.834 0.8 (20.6, 2.2) 21.3 (26.4, 3.8) 0.434
Secondary metabolic outcomes
LDL (mg/dl) 108 (105, 111) 118 (105, 130) 0.131 22.1 (25.0, 0.7) 25.7 (216.8, 5.3) 0.536
HDL (mg/dl) 38.3 (37.3, 39.4) 36.8 (32.7, 40.9) 0.454 2.5 (1.7, 3.3) 2.1 (20.9, 5.1) 0.829
Triglycerides (mg/dl) 165 (154, 176) 160 (112, 207) 0.829 25.4 (215.5, 4.7) 11.1 (227.9, 50.1) 0.424
Hemoglobin (A1c) HbA1c 6.4 (6.3, 6.6) 6.8 (6.1, 7.5) 0.289 20.1 (20.1, 0.0) 20.2 (20.5, 0.2) 0.564
Systolic (mm Hg) 128 (126, 129) 118 (112,123) 0.001 0.7 (20.8, 2.3) 3.4 (22.4, 9.3) 0.385
Diastolic (mm Hg) 79 (78, 80) 73 (68, 77) 0.008 0.0 (21.0, 1.0) 2.2 (21.4, 5.9) 0.249
NOT HIGH5 less than five binge episodes per week; HIGH BINGE5greater or equal to five binge episodes per week.
aUnadjusted means at baseline.
bPredicted 12-month changes for each outcome variable based on linear mixed models. Independent variables included time (3 or 12 months), treatment arm, baseline
value of the outcome variable, binge eating status [NOT HIGH (reference) vs. HIGH BINGE], time, and time by binge eating status interaction.
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and not obtaining weight loss treatment or who obtain weight loss
treatment outside of a research study; do not seek care through the
VHA; are from other parts of the country; are female or younger.
Another concern in this study was the clinical meaningfulness of the
low weight losses observed. This, combined with the short time
frame of the entire study (12 months), may have accounted for the
absence of significant dietary and metabolic improvements. On the
other hand, a 5–10% weight loss has clinically meaningful health
benefits and while only 4% of HIGH BINGE veterans achieved this,
20–25% of all other veterans lost at least 5% of body weight. A
final limitation was the potentially insufficient sample size (n5 24)
in the HIGH BINGE category to detect differences in some
outcomes.
Our findings have immediate and important policy implications for
the assessment of binge eating behavior among veterans. The binge
item discriminates amongst veterans who will be successful in
weight management treatment, is easily disseminated (self-report
and low burden), and has been retained in the newest condensed
version of the MOVE!23 Survey (MOVE!11). There are also impor-
tant research implications. Replication, particularly with a larger
sample size, is needed. The first step in remedying the disparities in
weight loss outcome will be to test treatments for BED in the VHA
system. Treatment completion findings from this study suggest that
binge eating veterans will likely engage in treatment.
One question raised by these findings is whether MOVE! is contra-
indicated for veterans with high-frequency binge eating because they
gained weight. An alternative view is that treatment helped to slow
the rate of weight gain for those binge eaters who would thus have
fared worse without treatment. Like previous research reporting
steep weight gain trajectories prior to MOVE! participation (32,33),
we found that on average, ASPIRE study participants had gained
2.9 kg (95% CI: 1.7, 4.2) in the 12 months prior to study initiation.
Interestingly, there were no significant differences in pretreatment
weight trajectories between the binge groups in this study, in con-
trast to a new study that found significantly greater weight trajecto-
ries in primary care patients with overweight/obesity who were seek-
ing weight loss treatment and met DSM-5 criteria for BED,
compared to those who did not (34). Regardless, it is possible that
weight gain was attenuated during MOVE! participation with the
any binge group losing 1.6 kg and the high binge group gaining
only 1.6 kg, compared to a pretreatment weight gain of 2.9 kg.
In summary, this is the first study to demonstrate that binge eating
behavior predicts poor weight loss outcome, but not poor retention,
among veterans with overweight/obesity participating in a weight
loss treatment study. It also demonstrated that the single, self-report
MOVE!23 binge eating frequency item was successful in identifying
two important subgroups of the Veteran population. One group, the
any binge eaters, represented over three-quarters of this population,
and was less successful at weight loss than those without binge eat-
ing. The second group, the high-frequency binge eaters, was the
most vulnerable subgroup. Although they comprised only 6% of the
Veteran population who is overweight/obese, this group actually
gained weight during the course of weight management treatment.
Collectively, these findings highlight the need for specific interven-
tions to address binge eating in veterans, particularly high-frequency
binge eating. Finally, there are important implications for opera-
tional implementation of MOVE! and other weight loss programs as
well as for national VHA policy. Consideration should be given to
strategies that specifically address BED within the context of weight
loss programs. Medical teams providing primary care in VHA may
benefit from understanding this subpopulation of patients with over-
weight/obesity. The policy implications stemming from this research
may lead to national treatment expertise among clinicians.O
VC 2014 The Obesity Society
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